What is Neurobiological Technologies Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Neurobiological Technologies's interest expense for the
three
months ended in Sep. 2009 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2009 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Neurobiological Technologies's Operating Income for the
three
months ended in Sep. 2009 was $ 5.15 Mil. Neurobiological Technologies's Interest Expense for the
three
months ended in Sep. 2009 was $ 0.00 Mil.
Neurobiological Technologies has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Neurobiological Technologies Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurobiological Technologies (OTCPK:NTII) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Neurobiological Technologies's Interest Expense for the
three
months ended in Sep. 2009 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Sep. 2009 was $5.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2009 was $0.00 Mil.
Neurobiological Technologies's Interest Coverage for the quarter that ended in Sep. 2009 is calculated as
| Neurobiological Technologies had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Neurobiological Technologies (Neurobiological Technologies) Business Description
Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
| Ariel Warszawski |
10 percent owner |
C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176 |
| Ryan Heslop |
10 percent owner |
C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176 |
| Firefly Management Co Gp, Llc |
10 percent owner |
C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176 |
| Fvp Gp, Llc |
10 percent owner |
C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176 |
| Firefly Value Partners, Lp |
10 percent owner |
426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940 |
| Fvp Master Fund Lp |
10 percent owner |
FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176 |
| John B Stuppin |
director |
|
| Abraham E Cohen |
director |
500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018 |
| Abraham D Sofaer |
director |
HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010 |
| Biotechnology Value Fund L P |
other: Direct Beneficial Owner |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Bvf Partners L P/il |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Inc/il |
10 percent owner |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Biotechnology Value Fund Ii Lp |
other: Direct Beneficial Owner |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Bvf Investments Llc |
other: Direct Beneficial Owner |
1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
| Mark N Lampert |
10 percent owner |
1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Neurobiological Technologies (Neurobiological Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTII has been successfully added to your 